MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dyskinesias"

  • 2025 International Congress

    The Feedback Loop: Illness Perceptions and Motor Complications in Parkinson’s

    V. Azoidou, L. Smith, A. Noyce, C. Simonet (London, United Kingdom)

    Objective: To explore the relationship between motor complications, illness perceptions and cognitive beliefs about symptoms in people with Parkinson's disease (PwP). Background: Around 50% PwP…
  • 2025 International Congress

    Clinical Differences Among Parkinson’s Disease Patients Carrying GBA1 Variants in Colombia: Insights From LARGE-PD Consortium

    T. Lopez Gonzalez, S. Poveda, HM. Chaparro Solano, J. Ramchandra, E. Waldo, L. Santiago, T. Leal, M. Inca, O. Bernal-Pacheco, G. Arboleda Bustos, H. Arboleda, C. Cerquera, L. Quintero-Giraldo, C. Moreno-Gonzalez, B. Muñoz-Ospina, JL. Orozco, DA. Pineda, O. Buritica, D. Aguillon, M. Jimenez-Del Rio, C. Velez-Pardo, IF. Mata (Cleveland, USA)

    Objective: To compare the clinical manifestations of GBA1 variants p.K198E, p.E326K, and p.N370S in Parkinson’s disease(PD) patients in Colombia. Background: GBA1 variants have been identified…
  • 2025 International Congress

    Improved Decision-Making for In-Hospital Medication Management in Parkinson’s Disease

    R. Diaz-Rincon, M. Liang, A. Ramirez-Zamora, B. Shickel (Gainesvile, USA)

    Objective: To enhance clinical decision-making in PD management by developing and validating a conformal prediction framework that forecasts Levodopa Equivalent Daily Dose (LEDD) changes with…
  • 2025 International Congress

    Treatment Of Advanced Parkinson’s With Levodopa–Entacapone–Carbidopa Intestinal Gel – Impact On Dyskinesia

    B. Amlani, N. Smith (Reading, United Kingdom)

    Objective: To evaluate the effect of long-term treatment with levodopa–entacapone–carbidopa intestinal gel (LECIG) infusion on daily time with dyskinesia in people with advanced Parkinson’s disease…
  • 2025 International Congress

    Novel CUX2 Mutation Identified in Patient with Clinical Paroxysmal Nonkinesigenic Dyskinesia

    C. Cheung, G. Osaki Mark, K. Mackenzie (Elk Grove, USA)

    Objective: In this case, we present a novel mutation in the regulatory region for CUX-2 that is associated with clinical PNKD. Background: Paroxysmal nonkinesigenic dyskinesias…
  • 2025 International Congress

    Effect of Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa on motor fluctuations, dyskinesia, and sleep; subjective vs. PKG watch recordings.

    M. Bradley, E. Donlon, A. Gallagher, C. O'Keefe, J. Inocentes, F. Ruggieri, R. Reilly, R. Walsh, T. Lynch, C. Fearon (Dublin, Ireland)

    Objective: To evaluate the impact of continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa on bradykinesia, dyskinesia, and sleep quality using self-reported Hauser diaries and Parkinson’s KinetiGraph…
  • 2025 International Congress

    Paroxysmal Nonkinesigenic Dyskinesia in GLUT1 Deficiency Syndrome: A Rare Manifestation

    A. Medhus, E. Krause (Austin, USA)

    Objective: We describe a rare case of paroxysmal nonkinesigenic dyskinesia (PKND) in a patient with GLUT1 deficiency syndrome (GLUT1-DS). Background: Various movement disorders are a…
  • 2025 International Congress

    Antidepressants Associated with Worsening Dyskinesia in Parkinson’s Disease

    JV. Costa, EF. Muricy, FS. Brito, GS. Nunes, SC. Baran, GV. de Vasconcelos, CF. Do Nascimento, NS. Dos Santos, JX. Oliveira, ME. Vassoler, FG. Nascimento, AM. Guerra, RB. Kauark (Salvador, Brazil)

    Objective: This case report aims to highlight the impact of increasing venlafaxine dose on the worsening of dyskinesias and the onset of ocular dyskinesia³ and…
  • 2025 International Congress

    Facial Synkinesis: Can It Have a Central Origin?

    J. Patino (Houston, USA)

    Objective: To describe a case of left facial synkinesis in a patient with a right middle cerebral artery stroke. Background: Facial synkinesis has been classically…
  • 2025 International Congress

    Unraveling the Variability in Amantadine Response for Levodopa-Induced Dyskinesias: The Impact of Clinical and Genetic Factors

    L. Saadatpour, H. Chaparro-Solano, J. Yu, C. Sonneborn, C. Piccinin, S. Anis, E. Assaedi, P. Coss, S. Horn, O. Vaou, I. Mata, H. Fernandez (San Antonio, USA)

    Objective: To identify demographic, clinical, and genetic factors associated with the outcomes of amantadine treatment in dyskinetic Parkinson’s disease (PD) patients. Background: While recent advancements…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 44
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley